AcuCort AB (ACUC.ST)

SEK 0.73

(2.11%)

Gross Profit Summary of AcuCort AB

  • AcuCort AB's latest annual gross profit in 2023 was 6.59 Million SEK , up 31.24% from previous year.
  • AcuCort AB's latest quarterly gross profit in 2024 Q2 was 1.27 Million SEK , up 7.5% from previous quarter.
  • AcuCort AB reported a annual gross profit of 5.02 Million SEK in annual gross profit 2022, up 45.05% from previous year.
  • AcuCort AB reported a annual gross profit of 3.46 Million SEK in annual gross profit 2021, up 126.68% from previous year.
  • AcuCort AB reported a quarterly gross profit of 1.27 Million SEK for 2024 Q2, up 7.5% from previous quarter.
  • AcuCort AB reported a quarterly gross profit of 2.81 Million SEK for 2023 Q4, up 63.68% from previous quarter.

Annual Gross Profit Chart of AcuCort AB (2023 - 2016)

Historical Annual Gross Profit of AcuCort AB (2023 - 2016)

Year Gross Profit Gross Profit Growth
2023 6.59 Million SEK 31.24%
2022 5.02 Million SEK 45.05%
2021 3.46 Million SEK 126.68%
2020 1.52 Million SEK 0.0%
2019 - SEK 0.0%
2018 - SEK 0.0%
2017 - SEK 0.0%
2016 - SEK 0.0%

Peer Gross Profit Comparison of AcuCort AB

Name Gross Profit Gross Profit Difference
AlzeCure Pharma AB (publ) -476 Thousand SEK 1484.874%
BioGaia AB (publ) 950.19 Million SEK 99.306%
Enzymatica AB (publ) 31.86 Million SEK 79.311%
Enorama Pharma AB (publ) -3.9 Million SEK 268.982%
Gabather AB (publ) - SEK -Infinity%
Klaria Pharma Holding AB (publ.) -9000.00 SEK 73344.444%
Moberg Pharma AB (publ) -2.09 Million SEK 414.054%
Nanexa AB (publ) 59.15 Million SEK 88.857%
Newbury Pharmaceuticals AB (publ) 16.03 Million SEK 58.885%
ODI Pharma AB -1.34 Million SEK 591.341%
Orexo AB (publ) 549.9 Million SEK 98.801%
Probi AB (publ) 220.21 Million SEK 97.007%
Swedencare AB (publ) 164.8 Million SEK 96.0%
Swedish Orphan Biovitrum AB (publ) 14.05 Billion SEK 99.953%
Toleranzia AB -919 Thousand SEK 817.301%
Vivesto AB -10.65 Million SEK 161.862%